Date:11/2/2010

containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.Cannabis Science Inc.

Cannabis Science Inc.Dr. Robert J. Melamede

Mark J. FriedmanPresident & CEO

Investor Relationsinfo@cannabisscience.com

info@cannabisscience.comwww.cannabisscience.com

www.cannabisscience.com 1-888-889-0888

1-877-431-CBIS (2247)
'/>"/>

SOURCE Cannabis Science, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Medical Cannabis University™ Launches, Puts Thousands Back to Work to Help Veterans and the Chronically Ill
2. DC Patients Cooperative Urges Changes to the Proposed Medical Cannabis Marijuana Regulations
3. Cannabis Science Issues Guidance on Its Progress Toward FDA Investigative New Drug Applications For Clinical Trials and Proposed Dividend Payout for Current Shareholders to Receive a New Class of Common Stock
4. CNBC, Discovery Channel and National Geographic to Cover Dr. Robert Melamede and Richard Cowan of Cannabis Science Whom are Speaking at The Marijuana Conference in New York City on Oct. 25 & 26
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
7. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
8. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule